hrcak mascot   Srce   HID

Libri Oncologici : Croatian Journal of Oncology, Vol.45 No.2-3 Prosinac 2017.

Pregledni rad

Novelties in immunotherapy of esophageal and stomach cancer

Vesna Bišof   ORCID icon orcid.org/0000-0002-2826-9664 ; Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia; Osijek University School of Medicine, Osijek, Croatia

Puni tekst: engleski, pdf (153 KB) str. 65-68 preuzimanja: 87* citiraj
APA 6th Edition
Bišof, V. (2017). Novelties in immunotherapy of esophageal and stomach cancer. Libri Oncologici, 45 (2-3), 65-68. Preuzeto s https://hrcak.srce.hr/192191
MLA 8th Edition
Bišof, Vesna. "Novelties in immunotherapy of esophageal and stomach cancer." Libri Oncologici, vol. 45, br. 2-3, 2017, str. 65-68. https://hrcak.srce.hr/192191. Citirano 15.08.2018.
Chicago 17th Edition
Bišof, Vesna. "Novelties in immunotherapy of esophageal and stomach cancer." Libri Oncologici 45, br. 2-3 (2017): 65-68. https://hrcak.srce.hr/192191
Harvard
Bišof, V. (2017). 'Novelties in immunotherapy of esophageal and stomach cancer', Libri Oncologici, 45(2-3), str. 65-68. Preuzeto s: https://hrcak.srce.hr/192191 (Datum pristupa: 15.08.2018.)
Vancouver
Bišof V. Novelties in immunotherapy of esophageal and stomach cancer. Libri Oncologici [Internet]. 21.12.2017. [pristupljeno 15.08.2018.];45(2-3):65-68. Dostupno na: https://hrcak.srce.hr/192191
IEEE
V. Bišof, "Novelties in immunotherapy of esophageal and stomach cancer", Libri Oncologici, vol.45, br. 2-3, str. 65-68, Kolovoz 2018. [Online]. Dostupno na: https://hrcak.srce.hr/192191. [Citirano: 15.08.2018.]

Sažetak
A high frequency of somatic mutations has been detected in stomach and esophageal cancers which makes them a possible suitable target for the application of immunotherapy. Contemporary immunotherapeutic approaches rely on monoclonal antibodies that inhibit immune checkpoints. The results of early clinical studies are promising, while only a few phase III studies have published their results so far. A particulary promising treatment strategy is the combination of checkpoint inhibitors with other treatment modalities, such as chemotherapy, targeted therapy, radiotherapy or T cells agonists.

Ključne riječi
esophageal cancer; gastric cancer; checkpoint inhibitors; immunotherapy

Hrčak ID: 192191

URI
https://hrcak.srce.hr/192191

[hrvatski]

Posjeta: 119 *